Early-Stage Clinical Trial of AI-Driven CBCT-Guided Adaptive Radiotherapy for Lung Cancer
Project Number5R21EB033994-02
Contact PI/Project LeaderKESARWALA, APARNA
Awardee OrganizationEMORY UNIVERSITY
Description
Abstract Text
PROJECT SUMMARY
Stereotactic body radiation therapy (SBRT) is a highly effective treatment for early-stage non-small cell lung
cancer, but its accuracy can be compromised by multiple factors. There is an interval between simulation and
the first day of treatment, the size and position of targets and organs at risk can shift over a course of
treatment, and the thorax is in constant multidimensional motion. Adaptive radiation can improve the accuracy
of SBRT, but implementing it within the workflow of a busy radiation oncology clinic currently requires re-
simulation and re-planning, costing valuable departmental time and resources. Cone beam computed
tomography (CBCT) scans are obtained daily prior to the delivery of each fraction, but their utility for adaptive
radiation therapy has been limited by their image quality. Processing time also remains a significant barrier for
real-time deep learning-based methodologies. The objective of our proposed research is therefore to develop,
validate, and test in an early clinical trial the feasibility of using our two-part cone-beam computed tomography-
based deep learning method for dose verification based on rapid and accurate generation of high quality
synthetic CTs and multi-organ segmentation. In this project, we will pursue two Specific Aims: 1) to develop
and refine CBCT-based synthetic CTs for CBCT quality improvement, and 2) to evaluate the clinical feasibility
of our synthetic CT-based dose verification. The early clinical trial will prospectively enroll patients with early-
stage non-small cell lung cancer receiving definitive SBRT. Validation of the feasibility of this method is a
necessary intermediate step towards our longer-term goal of the implementation of real-time lung cancer
adaptive radiation, which will allow for increased accuracy of higher dose to target volumes and lower doses to
organs at risk, thereby improving local control and decreasing radiation-related risks and toxicities for patients
with non-small cell lung cancer.
Public Health Relevance Statement
PROJECT NARRATIVE
We propose to develop and validate a two-part deep learning method for dose verification in patients with
early-stage non-small cell lung cancer receiving definitive stereotactic body radiation therapy. We will evaluate
feasibility in a prospective early-stage clinical trial, a necessary intermediate step prior to the implementation of
real-time daily adaptive radiation therapy. Our long-term goal is to use real-time adaptive radiation therapy to
improve tumor control and decrease radiation-related toxicities for patients receiving radiation therapy for lung
cancer.
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
066469933
UEI
S352L5PJLMP8
Project Start Date
01-May-2023
Project End Date
30-April-2026
Budget Start Date
01-May-2024
Budget End Date
30-April-2025
Project Funding Information for 2024
Total Funding
$195,625
Direct Costs
$125,000
Indirect Costs
$70,625
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Biomedical Imaging and Bioengineering
$195,625
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R21EB033994-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R21EB033994-02
Patents
No Patents information available for 5R21EB033994-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R21EB033994-02
Clinical Studies
No Clinical Studies information available for 5R21EB033994-02
News and More
Related News Releases
No news release information available for 5R21EB033994-02
History
No Historical information available for 5R21EB033994-02
Similar Projects
No Similar Projects information available for 5R21EB033994-02